Polymers have played an integral role in the advancement of drug delivery technology by
providing controlled release of therapeutic agents in constant doses over long periods …

The transfer of polymer–protein conjugates into routine clinical use, and the clinical
development of polymer–anticancer-drug conjugates, both as single agents and as …

The discovery of new molecular targets and the subsequent development of novel
anticancer agents are opening new possibilities for drug combination therapy as anticancer …

Disseminated metastatic breast cancer needs aggressive treatment due to its reduced
response to anticancer treatment and hence low survival and quality of life. Although in …

The concept of polymer–drug conjugates was proposed more than 30 years ago, and an N-
(2-hydroxypropyl) methacrylamide (HPMA) copolymer conjugate of doxorubicin covalently …

Copolymers of N-(2-hydroxypropyl) methacrylamide (HPMA) are prototypic and well-
characterized polymeric drug carriers that have been broadly implemented in the delivery of …

The clinical success of polypeptides as polymeric drugs, covered by the umbrella term
“polymer therapeutics,” combined with related scientific and technological breakthroughs …

Polypeptides are envisaged to achieve a major impact on a number of different relevant
areas such as biomedicine and biotechnology. Acquired knowledge and the increasing …

Copolymers based on N-(2-hydroxypropyl) methacrylamide (HPMA) are prototypic and well-
characterized polymeric drug carriers that have been broadly implemented in the delivery of …

Introduction: Combination therapy with multiple therapeutic agents has wide applicability in
medical and surgical treatment, especially in the treatment of cancer. Thus, new drug …